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Abstract
BACKGROUND
Gynecological malignancies represent a major cause of death in women and are
often treated with platinum-based regimens. Patients undergoing chemotherapy
suffer from alterations in nutritional status which may worsen gastrointestinal
(GI) toxicities, quality of life and affect the overall prognosis. Indeed, assuring a
good nutritional status and limiting toxicities during treatment are still major
goals for clinicians.
AIM
To assess the role of Mediterranean Diet (MD) in reducing GI toxicities in patients
with gynecological cancers treated with platinum-based regimens.
METHODS
We conducted an observational study on 22 patients with gynecological tumors
treated with a platinum-based chemotherapy at Candiolo Cancer Institute
FPO/IRCCS between January 2018 and June 2018. The food and frequency (FFQ)
and the Patient-Reported Outcomes Common Terminology Criteria For Adverse
Events (PRO-CTCAE) questionnaires were administered at baseline and at every
Day 1 of each cycle. To evaluate the differences in GI toxicities the study
population was divided in two groups according to the currently validated
Mediterranean Diet Serving Score (MDSS) at baseline.
RESULTS
Patients with high MDSS reported a trend toward lower GI toxicities according to
PRO-CTCAE at each timepoint (first evaluation: P = 0.7; second: P = 0.52; third: P
= 0.01). In particular, difference in nausea frequency and gravity (P < 0.001),
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stomach pain frequency and gravity (P = 0.01 and P = 0.02), abdomen bloating
frequency and gravity (P = 0.02 and P = 0.03), and interference with daily
activities (P = 0.02) were highly statistically significant at the end of treatment.
More than 60% of patients changed their food habits during chemotherapy
mainly because of GI toxicities. A higher reduction of food intake, both in terms
of caloric (P = 0.29) and of single nutrients emerged in the group experiencing
higher toxicity.
CONCLUSION
Our results show that adherence to MD possibly reduces GI toxicity and prevents
nutritional status impairment during chemotherapy treatment. Bigger studies are
needed to confirm our results.
Key words: Mediterranean diet; Gynecological malignancies; Gastrointestinal toxicities;
Platinum-based chemotherapy; Nutritional status
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Core tip: Mediterranean diet possibly reduces gastro-intestinal toxicities and nutritional
status impairment related to platinum-based chemotherapy in women affected by
gynecological cancers.
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INTRODUCTION
In 2017 gynecological  cancers (endometrium, cervix,  and ovarian) accounted for
approximately 12% (94990 out of 810320) of all new cancer diagnoses in women in the
United States. Ovarian cancer (OC) and cervical cancers represent 1.3% and 0.7% of
new cancer cases, respectively, in United States with OC ranks fifth in cancer deaths
among women, accounting for more deaths than any other gynecological cancer[1,2].
Current  standard  treatment  for  gynecological  cancers  is  represented  by  a
multimodal  approach  including  surgery,  chemotherapy,  radiotherapy (RT)  and
brachytherapy. Platinum agents (cisplatin and carboplatin) are the most often used
drugs in these malignancies, both alone or in combination with other agents (i.e.,
carboplatin-taxol in OC and endometrial cancer, in association with bevacizumab in
cervical cancer) or radiotherapy (i.e. weekly cisplatin + RT in locally advanced cervical
cancer)[3-7].  Expected  toxicities  from  platinum  based  chemotherapy  are  mainly
hematological  and  gastrointestinal  (GI)  (nausea,  vomiting,  diarrhea,  or
constipation)[8,9].
GI system does of course play a central role in nutritional modulation, but due to its
direct exposure to diet intakes and its rapid cellular turnover and plasticity it is also
affected by chemotherapy-induced toxicities and subject to nutritional stimuli. Food
substances could therefore be able to modulate chemotherapy-induced GI toxicities,
as suggested by recent studies[10,11].
Cancer patients are often subjected to alterations in nutritional status due to both
disease and treatment-related toxicities; indeed impairment in nutritional status could
worse patients’ quality of life (QoL), lead to treatments’ doses modifications and
schedule delays and finally affect the prognosis. Proposed nutritional interventions
should have the following aims: Prevention and early treatment of symptoms due to
chemotherapy, QoL improvement and avoidance of complications such as overweight
on one side and cachexia on the other[12,13].
It is estimated that half of all patients with cancer eventually develop a cachectic
syndrome during treatment and 70% of terminal patients suffer from this condition,
which is the recognized cause of the 20% of all cancer deaths[14]. Cancer cachexia is
characterized by systemic inflammation, negative protein and energy balance, and an
involuntary loss of body mass. Recent therapies for the cachectic syndrome involve a
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multidisciplinary approach combining palliative therapy with orexigenic appetite
stimulants and diet  modification and/or exercise[15,16].  More recently the specific
evaluation of food intake has been proposed as an important tool to prevent the onset
of nutritional impairments[17].
It  is  well  recognized  that  processed  meat  promote  inflammation  due  to  the
presence of nitrites[18,19] and patients with high intake of “inflammatory” foods were
found with greater levels of PCR, sICAM, IL-6, E-selectin, and homocysteine[20]. On
the opposite,  lower values of the same markers were found for those consuming
higher intake of wholegrain cereals, nuts, vegetables, fruit and tea[21,22]. As if the above
reported studies could suggest a diet with low content of animal proteins, it should be
considered that a vegan diet could easily determine nutritional deficiencies,  and
should  be  particularly  avoided  in  cancer  patients  considering  the  high  risk  of
malnutrition[23].
In this context a valid alternative model represented by the Mediterranean Diet
(MD) has already showed to assure well-balanced food intake and potentially play an
anti-inflammatory role[24-26]. Figure 1 shows recommended daily nutritional intakes
according to the MD model by the Mediterran Diet Foundation[27].
Numerous  studies  have  already  demonstrated  a  relationship  between  MD
adherence and the prevention of cardiovascular diseases and diabetes. Moreover,
Monteagudo et al[28] have validated the Mediterranean Diet Serving Score (MDSS) as
an  easy,  valid,  and  accurate  instrument  to  assess  MD  adherence  based  on  the
consumption of foods and food groups per meal, day, and week (range 0 to 24 points).
However, despite the recognized importance of prevent early onset of nutritional
impairments in cancer patients assuring the maintenance of a good QoL and the
relevance of  gynecological  cancers,  few studies have explored the role of  MD in
preventing chemotherapy toxicities.
We aim to conduct an observational study to assess the role of MD in reducing GI
toxicities  in  patients  with  gynecological  cancers  treated  with  chemotherapeutic
platinum-based regimens according to their adherence to the MDSS.
MATERIALS AND METHODS
Ethic statement
We conducted an observational  study on 24 patients  with gynecological  tumors
treated with a platinum-based chemotherapy at Candiolo Cancer Institute (FPO-
IRCCS) between January 2018 and June 2018. Patients affected by intestinal chronic
disease or any other chronic condition which could impact on GI toxicities or who
required parenteral nutrition were excluded from the study. All recruited patients
signed the written informed consent for observational study and the institutional
review board of our Institutions provided approval.
Patients
For each selected patient, the following clinico-histopathological data were recorded:
(1) Age; (2) Type of gynecological cancer (cervical, endometrial, ovarian); (3) Weight;
(4) Body mass index (BMI); (5) Smoke and alcohol habits; (6) Chemotherapy treatment
scheme; (7) Number of previous lines; and (8) Nutritional requirements [basal energy
expenditure (BEE) and total energy expenditure (TEE)].
At baseline, patients were interviewed by the dietician through the food frequency
questionnaire (FFQ) to evaluate food habits and intakes before the beginning of the
chemotherapeutic treatment. FFQ was then administered each two cycles (up to three
times for patients receiving 6 platinum-based cycles). Subsequent FFQs included two
questions about food intakes’ differences compared to baseline and their causes.
Patients  also  received  at  each  cycle  the  patients-reported  outcome  common
terminology criteria for adverse events (PRO-CTCAE) questionnaire for toxicities
assessment[29]. For this study, we decided to select only GI toxicities because of the
relevant association with nutritional aspects. Particularly, key elements evaluated
were the following: dry mouth feeling, swallowing difficulty, oral sores, cracks in
mouth’s corners, difficulty of tasting food and beverages’ flavor, loss of appetite,
nausea,  vomiting,  stomachache,  intestinal  gas,  abdominal  bloating,  constipation,
diarrhea, and abdomen ache.
Statistical analysis
Anthropometric and nutritional values were estimated using standard formula such
as BMI and Harris-Benedict formula {i.e., for female 655 + [9.56 × body weight (kg)] +
[1.85 × height (cm)] - [4.67 × age (years)]}. To understand patients’ TEE, the obtained
value was multiplied for 1.2-1.5, depending on the individual status (underweight,
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Figure 1
Figure 1  The recommended daily nutritional intakes according to the Mediterranean diet model by the Mediterranean Diet Foundation.
overweight exc.). BEE was estimated on the basis of actual body weight, except for
obese patients for whom BEE was adjusted to a “correct body weight” using the
following formula: (Actual body weight × 0.25) + ideal body weight. Average food
composition values,  derived from CREA and IEO databases,  were used to assess
individual food intake detected by FFQ[30,31]. Adherence to MD was evaluated using
MDSS (range 0-24), as reported above[28]. Patients were then divided in two groups
according to the different adherence: Low (from 0 to 12 points) and high (from 13 to
24).
We therefore compared FFQ and PRO-CTCAE results to assess diet variations and
toxicities profile during treatment in the two groups according to MDSS. A P < 0.05
was considered statistically significant. All analyses were performed using the SPSS
statistical software program, version 22.0 (IBM SPSS Inc., Chicago, IL, United States).
RESULTS
Baseline evaluation
Twenty-four patients were enrolled in our observational study following the inclusion
criteria.  There  were  2  drop-out  due  to  premature  interruption  of  the  treatment.
Therefore,  only  22  patients  completed  all  questionnaires’  time-points  and were
included in our analysis. Complete baseline patients’ clinical data are reported in
Table 1.
According to the first FFQ, the majority of patients (59.10%) declared to have not
received any nutritional advice from any specialist before treatment beginning. About
half of them has independently searched information about nutrition and anti-cancer
treatments: in the 83.3% patients utilized websites for their search. Table 2 shows
anthropometric patients’ characteristics in the two groups of patients according to
MDSS. Groups were well balanced as there was no statistically significant difference
in median age (P = 0.11), weight (P = 0.34) and BMI (P = 0.6).
FFQ analysis
The analysis of the second FFQ showed that the majority of patients has changed food
habits from the beginning of chemotherapy treatment. For the 64% of the sample the
change was partial, for the 9% it was total. The presence of one or more GI symptoms
has been the cause of the change for about 70% of them. Loss of appetite was present
in 100% of them, followed by nausea (about 60%). Analysis of data showed a decrease
in average MDSS of both groups. Average coverage of the TEE has also decreased: It
is more than 100% in only 12 on 22 patients with a reduction in the group with higher
MSSD compared to the baseline. Table 3 shows nutritional features emerged from this
analysis. Questions in the third FFQ shows that about 60% of the sample has modified
food habits again compared with the previous evaluation. Between them, about 70%
has attributed the change to the presence of one or more GI symptoms. Even in this
case, loss of appetite has been reported by all of them. Nausea, dysgeusia and oral
sores  are  little  decreased  comparing  the  previous  analysis,  but  on  the  opposite
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Table 1  Clinical and nutritional characteristics of the sample at baseline
Characteristics n = 22
Age (yr, mean value) 61
Weight (kg, mean value ± SD) 64 ± 14.2
BMI (mean value ± SD) 25 ± 5.2
Allergies, n (%)
Yes 15 (68.2)
No 7 (31.8)
Smoke, n (%)
Yes 5 (22.7)
No 17 (77.3)
Alcohol, n (%)
Yes 8 (36.4)
No 14 (63.6)
Type of gynecological cancer, n (%)
Cervical cancer 5 (22.7)
Endometrial cancer 2 (9.1)
Ovarian cancer 15 (68.2)
Chemotherapy treatment, n (%)
Carboplatin 2 (9.2)
Carboplatin - Bevacizumab 1 (4.5)
Carboplatin - Caelyx 3 (13.6)
Carboplatin - Gemcitabine 2 (9.2)
Carboplatin - Taxol 9 (40.9)
Carboplatin - Gemcitabine - Bevacizumab 1 (4.5)
Cisplatin 3 (13.6)
Cisplatin – Bevacizumab 1 (4.5)
Number of lines, n (%)
I 14 (63.6)
II 7 (31.8)
III 1 (4.6)
Nutritional requirements
BEE in kcal (Average value ± SD) 1262.5 ± 146.6
TEE in kcal (Average value ± SD) 1678.9 ± 177.1
Mediterranean diet adherence
MDSS (mean value ± SD) 12.5 ± 3.4
MDSS ≥ 13, n (%) 12 (54.5)
MDSS < 13 10 (45.5)
SD: Standard deviation; MDSS: Mediterranean diet serving score; BMI: Body mass index; TEE: Total energy
expenditure; BEE: Basal energy expenditure.
stomachache  and  vomiting  are  increased.  Overall  a  comparative  analysis  of
nutritional intake from the beginning to the end of the evaluations underlined a
general reduction of all intakes and consequently of TEE coverage. Group with higher
MSSD suffered from a higher reduction of all intakes.
PRO-CTCAE analysis
Data from the PRO-CTCAE after the first chemotherapy cycle showed no statistically
significant differences between the two groups, except for “abdominal pain frequency
and gravity” which was higher in patients with MDSS < 13 (P = 0.04). Nevertheless,
group with  higher  MDSS showed a  tendency to  suffer  from less  toxicities.  This
difference emerged more clearly when looked at the total GI data where the mean
value differed of 1.7 points 13.4 vs 15.1).
Not  surprisingly,  when  evaluating  the  last  PRO-CTCAE  several  statistical
differences were reported between the two groups.  Particularly,  the group with
higher MDSS reported lower values of the following toxicities: Nausea frequency and
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Table 2  Anthropometric and nutritional characteristics of the two groups at the baseline
according to the Mediterranean diet adherence score
MDSS ≥ 13 MDSS < 13 Total
(n = 12) (n = 10) (n = 22)
Age (yr, mean value ± SD) 64.9 ± 11.6 56.4 ± 11.9 61 ± 12.2
Weight (kg, mean value ± SD) 61.3 ± 11.4 67.2 ± 17 64 ± 14.2
BMI (mean value ± SD) 24.5 ± 4.3 25.7 ± 6.3 25 ± 5.2
MDSS (mean value ± SD) 15.1 ± 2.1 9.5 ± 1.7 12.5 ± 3.4
Average daily intake
Proteins (g, mean value ± SD) 67.8 ± 15.6 83.5 ± 32 74.9 ± 25.1
Fats (g, mean value ± SD) 73.7 ± 21.9 91.6 ± 41.2 81.8 ± 32.6
Saturated fats (g, mean value ± SD) 25.8 ± 7.4 33.1 ± 19.9 29.1 ± 14.6
Carbohydrates (g, mean value ± SD) 227.5 ± 37.7 208.3 ± 80 218.8 ± 59.8
Sugars (g, mean value ± SD) 91 ± 15 85,9 ± 29 88,7 ± 22
Fibers (g, mean value ± SD) 22 ± 4.5 17.3 ± 6 19.9 ± 5.6
Energy intake (kcal, mean value ± SD) 1893.3 ± 376.3 2038.7 ± 724.8 1959.4 ± 552.1
Fluid intake (mL, mean value ± SD) 1320.8 ± 491.5 1365 ± 704 1340.9 ± 582.6
Coverage of the TEE (mean % ± SD) 115.8 ± 20.2 117.7 ± 41.6 116.7 ± 30.9
Coverage of the TEE > 100%, n (%) 10 (83.3) 5 (50) 15 (68.2)
SD: Standard deviation; MDSS: Mediterranean diet serving score; BMI: Body mass index; TEE: Total energy
expenditure.
gravity  (P  <  0.001),  stomachache frequency and gravity  (P  =  0.01  and P  =  0.02),
abdomen bloating frequency and gravity (P = 0.02 and P =0.03) and interference with
daily  activities  (P  =  0.02).  Difference  in  total  average  GI  toxicities  also  became
statistically significant between groups at this last evaluation (P = 0.01), but overall a
trend to lower GI toxicities according to CTCAE was observed at each timepoint (first
evaluation P  = 0.7; second: P  = 0, 52; and third: P  =0.01). Tables 4 and 5 reported
completed  and  extensive  data  from  the  first  and  last  PRO-CTCAE  assessment
respectively.
DISCUSSION
The Italian Association of Medical Oncology (AIOM) has recently highlighted the
importance for cancer patients to receive information from skilled professionals (i.e.,
dieticians, nutritionists and medical oncologists), regarding the nutritional status, its
possible  changes  during  chemotherapy  due  to  toxicities  and  the  negative
consequences[32]. Proposed nutritional interventions should aim to prevent and/or
limit treatments’ side effects, assuring well-balanced nutritional status and QoL[33,34].
However, our study shows that about 50% of the patients do not receive sufficient
information and nutritional advice before treatment.
First and second assessments combining FFQ and PRO-CTCAE did not show any
statistically significant differences between the two groups. However, a trend toward
lower GI toxicities  was seen in patients with high MDSS at  each timepoint (first
evaluation  P  =  0.7;  second:  P  =  0.52;  and  third:  P  =  0.01).  Difference  in  nausea
frequency and gravity (P < 0.001), stomachache frequency and gravity (P = 0.01 and P
=  0.02),  abdomen  bloating  frequency  and  gravity  (P  =  0.02  and  P  =  0.03)  and
interference with daily activities (P = 0.02) became highly statistically significant at the
end of treatment. Moreover, more than 60% of patients declared to have changed their
food habits during chemotherapy mainly because of GI toxicities. A higher reduction
of food intake, both in terms of caloric (P = 0.29) and of single nutrients emerged in
the group experienced higher toxicity. All together these results suggest a protective
role of MD in preventing cumulative GI chemotherapy induced toxic effects and
supporting  patients  nutritional  wellness  during  chemotherapy[35,36].  Of  note,  no
significant changes in body weight and BMI were observed in our study population
during treatment.
We recognize that our study has the several weaknesses: Although all patients were
treated with a platinum-based chemotherapy and were affected by a gynecologic
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Table 3  Nutritional-anthropometric features derived from the analysis of the second food
frequency questionnaire
MDSS ≥ 13 MDSS < 13 Total
(n = 12) ( n = 10) ( n = 22)
Weight (kg, mean value ± SD) 61 ± 11.3 67.2 ± 17.3 63.8 ± 14.3
BMI (mean value ± SD) 24.4 ± 4.3 25.7 ± 6.3 25 ± 5.2
MDSS (mean value ± SD) 13.3 ± 0.8 8.9 ± 2.6 11.3 ± 2.9
Average daily intake
Proteins (g, mean value ± SD) 56.1 ± 15.5 70.6 ± 34.2 62.7 ± 26.1
Fats (g, mean value ± SD) 60.6 ± 17.8 83 ± 29 70.8 ± 25.6
Saturated fats (g, mean value ± SD) 21.3 ± 6.6 27.5 ± 12 24.1 ± 9.7
Carbohydrates (g, mean value ± SD) 212.5 ± 55.9 215 ± 95.6 213.6 ± 74.5
Sugars (g, mean value ± SD) 87.9 ± 20.6 99 ± 37.9 93 ± 29.5
Fibers (g, mean value ± SD) 18.3 ± 5.5 18.7 ± 8.3 18.5 ± 6.8
Energy intake (kcal, mean value ± SD) 1633.8 ± 406.8 1921.7 ± 687.7 1764.6 ± 557.5
Fluid intake (mL, mean value ± SD) 1400 ± 495.5 1388.9 ± 416.7 1394.7 ± 427.5
Coverage of the TEE (%, mean value ± SD) 100.2 ± 24.5 110.4 ± 36.4 104.8 ± 30.1
Coverage of the TEE > 100%, n (%) 7 (58.3) 5 (50) 12 (54.5)
SD: Standard deviation; MDSS: Mediterranean diet serving score; BMI: Body mass index; TEE: Total energy
expenditure.
malignancy, it is undoubtable that size and heterogeneity of our population (in terms
of  cancer  type,  line  of  treatment,  and chemotherapy schedule),  which affect  the
statistical power, are important limitations. However, to our knowledge, this is the
first  observational  study investigating the possible  role  of  MD in preventing GI
toxicities. Further studies with larger cohorts of patients homogeneous for type of
disease and treatments,  might help to elucidate if  and how MD could impact on
treatment related GI toxicities.
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Table 4  Gastrointestinal toxicities’ score after first chemotherapy cycle in the whole study population and in the two study’s groups
according to the Mediterranean diet serving score
MDSS ≥ 13 MDSS < 13 Total P value
Dry mouth (G) 1 ± 1.3 1.1 ± 1.3 1 ± 1.3 0.85
Dysphagia (G) 0.3 ± 0.5 0.4 ± 0.7 0.3 ± 0.6 0.70
Oral sores (A) 0.2 ± 0.4 0.5 ± 1.3 0.3 ± 0.9 0.45
Oral sores (G) 0.1 ± 0.3 0.4 ± 1.3 0.2 ± 0.9 0.44
Mouth’s cracks (G) 0.1 ± 0.3 0.4 ± 1.3 0.2 ± 0.9 0.44
Dysgeusia (G) 0.9 ± 1.2 1 ± 1.2 1 ± 1.2 0.84
Loss of appetite (I.A) 1.1 ± 1.1 1.4 ± 1.5 1.2 ± 1.3 0.59
Loss of appetite (G) 1 ± 1 1.3 ± 1.7 1.1 ± 1.3 0.61
Nausea (F) 1.5 ± 1.1 1.4 ± 1.6 1.5 ± 1.3 0.86
Nausea (G) 1 ± 0.9 1.5 ± 1.7 1.2 ±1.3 0.38
Vomiting (F) 0.6 ± 0.8 0.6 ± 1.3 0.6 ± 1 1
Vomiting (G) 0.3 ± 0.5 0.6 ± 1.3 0.5 ± 1 0.46
Stomachache (F) 0.2 ± 0.6 0.7 ± 0.9 0.4 ± 0.8 0.13
Stomachache (G) 0.1 ± 0.3 0.5 ± 0.7 0.3 ± 0.6 0.08
Intestinal gas (yes/no) 0.4 ± 0.5 0.3 ± 0.5 0.4 ± 0.5 0.64
Bloating (F) 0.7 ± 0.9 0.5 ± 1 0.6 ± 0.9 0.62
Bloating (G) 0.3 ± 0.5 0.4 ± 0.7 0.4 ± 0.6 0.70
Constipation (G) 0.5 ± 0.5 0.7 ± 0.7 0.6 ± 0.6 0.44
Diarrhea (F) 0.7 ± 0.9 0.7 ± 1.3 0.7 ± 1.1 1
Abdomen ache (F) 1.1 ± 1 0.3 ± 0.7 0.7 ± 0.9 0.04
Abdomen ache (G) 0.8 ± 0.8 0.2 ± 0.4 0.5 ± 0.7 0.04
Abdomen ache (I.A) 0.7 ± 0.8 0.2 ± 0.6 0.5 ± 0.7 0.11
Toxicity (TOT) 13.4 ± 6.6 15.1 ± 14.5 14.2 ± 10.7 0.7
I.A: Interference with daily activities; MDSS: Mediterranean diet serving score; G: Gravity; F: Frequency; TOT: Time of treatment.
Table 5  Gastrointestinal toxicities’ score after last chemotherapy cycle in the whole study population and in the two study’s groups
according to the Mediterranean diet serving score
MDSS ≥ 13 MDSS < 13 Total P value
Dry mouth (G) 1.5 ± 1.8 0.8 ± 1.8 1.2 ± 1.7 0.53
Dysphagia (G) 0 ± 0 0.2 ± 0.4 0.1 ± 0.3 0.24
Oral sores (G) 0 ± 0 0 ± 0 0 ± 0 1
Oral sores (A) 0 ± 0 0 ± 0 0 ± 0 1
Mouth’s cracks (G) 0 ± 0 0.2 ± 0.4 0.1 ± 0.3 0.24
Dysgeusia (G) 1.3 ± 1.5 2.6 ± 1.9 1.9 ± 1.8 0.23
Loss of appetite (G) 1.3 ± 1.5 2.4 ± 1.7 1.8 ± 1.6 0.28
Loss of appetite (I.A) 1.3 ± 1.5 2 ± 1.4 1.6 ± 1.4 0.44
Nausea (F) 0.7 ± 1.6 3.6 ± 0.9 2 ± 2 < 0.01
Nausea (G) 0.7 ± 1.6 3.4 ± 0.9 1.9 ± 1.9 < 0.01
Vomiting (F) 0.3 ± 0.8 0.8 ± 1.3 0.5 ± 1 0.45
Vomiting (G) 0.2 ± 0.4 1 ± 1.7 0.5 ± 1.2 0.28
Stomach ache (F) 0 ± 0 1 ± 1 0.5 ± 0.8 0.03
Stomach ache (G) 0 ± 0 1.2 ± 1.3 0.5 ± 1 0.04
Gas (yes/no) 0.3 ± 0.5 0.4 ± 0.5 0.4 ± 0.5 0.74
Bloating (F) 0 ± 0 1.4 ± 1.3 0.6 ± 1.1 0.02
Bloating (G) 0 ± 0 1 ± 1 0.5 ± 0.8 0.03
Constipation (G) 0.8 ± 0.4 2.4 ± 1.8 1.5 ± 1.4 0.06
Diarrhea (F) 0.5 ± 0.8 1.2 ± 1.1 0.8 ± 1 0.25
Abdomen ache (F) 0.2 ± 0.4 1.4 ± 0.9 0.7 ± 0.9 0.01
Abdomen ache (G) 0.2 ± 0.4 1.2 ± 0.8 0.6 ± 0.8 0.02
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Abdomen ache (I.A) 0.2 ± 0.4 1.2 ± 0.8 0.6 ± 0.8 0.02
GI toxicity (TOT) 9.5 ± 10.9 29.4 ± 10.4 18.5 ± 14.5 0.01
I.A: Interference with daily activities; MDSS: Mediterranean diet serving score; G: Gravity; F: Frequency; TOT: Time of treatment; GI: Gastrointestinal.
ARTICLE HIGHLIGHTS
Research background
Gynecological cancers still account for approximately 12% of all new cancer diagnoses in women
and are often treated with platinum-based chemotherapy scheme. Cancer patients are often
subjected to alterations in nutritional status due to both disease and treatment-related toxicities,
especially  gastrointestinal  (GI)  ones.  Indeed impairment  in  nutritional  status  could worse
patients’ quality of life (QoL), lead to treatments’ doses modifications and schedule delays and
finally affect the overall prognosis.
Research motivation
The Mediterranean Diet (MD) model has already showed to assure a well-balanced food intake
and  potentially  play  an  anti-inflammatory  role.  Moreover,  several  studies  have  already
demonstrated a relationship between MD adherence and the prevention of cardiovascular and
metabolic diseases and diabetes. More recently, Monteagudo and colleagues have validated the
Mediterranean Diet Serving Score (MDSS) as an easy, valid, and accurate instrument to assess
MD adherence[28].  Despite  the recognized importance of  prevent  early onset  of  nutritional
impairments in cancer patients assuring the maintenance of a good QoL and the relevance of
gynecological cancers, few studies have explored the role of MD in preventing chemotherapy
toxicities.
Research objectives
We aim to conduct an observational study to assess the role of MD in reducing GI toxicities in
patients  affected by gynecological  cancers  treated with  chemotherapeutic  platinum-based
regimens according to their adherence to the MDSS.
Research methods
We conducted an observational study on 24 patients with gynecological tumors treated with a
platinum-based chemotherapy at Candiolo Cancer Institute (FPO-IRCCS) between January 2018
and June 2018. Patients affected by intestinal chronic disease or any other chronic condition,
which could impact on GI toxicities were excluded from the study. Patients were interviewed at
baseline by the food frequency questionnaire (FFQ) to evaluate food habits and intakes before
the beginning of the chemotherapeutic treatment. FFQ was then administered each two cycles
(up to three times for patients receiving 6 platinum-based cycles). Patients also received at each
cycle the patients-reported outcome common terminology criteria for adverse events (PRO-
CTCAE) questionnaire for GI toxicities assessment[29]. Furthermore, anthropometric assessments
[weight; body mass index (BMI); basal energy expenditure; and total energy expenditure] were
measured at each cycle.
Research results
Our study showed a trend toward lower GI  toxicities  in  patients  with high MDSS at  each
timepoint (first evaluation: P = 0.7; second: P = 0, 52; and third: P =0.01). Difference in nausea
frequency and gravity (P < 0.001), stomachache frequency and gravity (P = 0.01 and P = 0.02),
abdomen bloating frequency and gravity (P  = 0.02 an P  = 0.03), and interference with daily
activities (P  = 0.02) became highly statistically significant at the end of treatment. A higher
reduction of food intake, both in terms of caloric (P = 0.29) and of single nutrients emerged in the
group experienced higher toxicity. Of note, no significant changes in body weight and BMI were
observed in our study population during treatment, even if more than 60% of patients declared
to have changed their food habits during chemotherapy mainly because of GI toxicities.
Research conclusions
Both FFQ and PRO-CTCAE results in our series suggest a protective role of MD in preventing
cumulative GI chemotherapy induced toxic effects and supporting patients nutritional wellness
during chemotherapy. However, our study also showed that about 50% of the patients declare to
not receive sufficient information and nutritional advice before treatment, pawing the way for a
better effort to assure patients high-quality comprehensive care.
Research perspectives
This is the first observational study investigating the possible role of MD in preventing GI
toxicities in gynecological cancer patients. Further studies with larger cohorts of patients might
help to confirm if and how MD could impact on treatment related GI toxicities. The Italian
Association of Medical Oncology (AIOM) has recently highlighted the importance for cancer
patients to receive information from skilled professionals (i.e.,  dieticians,  nutritionists,  and
medical oncologists), regarding the nutritional status, its possible changes during chemotherapy
due to toxicities and the negative consequences. Future nutritional interventions should aim to
prevent treatments’ side effects, assuring well-balanced nutritional status and QoL.
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